GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NanoViricides Inc.
NanoViricides is a biotech company developing drugs to treat viral infections based on its unique nano-platform. Its stock price is a speculative bet on a breakthrough in this technology. The stock price is volatile and driven by news from the lab.
Share prices of companies in the market segment - Pharma virus
NanoViricides is a biopharmaceutical company that has developed a unique platform for creating nanoparticles that mimic human cells to destroy viruses. We've categorized it under "Pharma: Viruses." The chart below shows how the market values innovative antiviral technologies.
Broad Market Index - GURU.Markets
NanoViricides is a biopharmaceutical company developing nanotechnology-based drugs for the treatment of viral infections. Its innovative platform makes it part of the GURU.Markets index. The chart below compares its performance, reflecting investor expectations, with the overall market picture.
Change in the price of a company, segment, and market as a whole per day
NNVC - Daily change in the company's share price NanoViricides Inc.
NanoViricides, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its antiviral drugs.
Daily change in the price of a set of shares in a market segment - Pharma virus
NanoViricides, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with NNVC's performance, with its unique virus-fighting platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
NanoViricides develops nanotechnology-based drugs to combat viral infections. This innovative biotech company's shares are driven by research data. Its story exemplifies the biotech sector's contribution to overall market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NanoViricides Inc.
For NanoViricides, Inc., the year-over-year performance is a story of developing its unique platform for combating viral diseases. Its 12-month market cap depends entirely on progress in preclinical and clinical trials. The success of its "nanoviricides" could offer a new approach to treating viruses such as influenza, herpes, and COVID-19.
Annual dynamics of market capitalization of the market segment - Pharma virus
NanoViricides, Inc. is developing a new class of antiviral drugs. Its stock price is entirely speculative and based on investor confidence in its unique scientific platform rather than current financial results, which is typical for early-stage biotech.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NanoViricides, with its antiviral drug development platform, is one of the most speculative stories in biotech. Its stock price is completely unrelated to the economy, driven instead by news of its trials. Its price is a roller coaster, reflecting the faith of the most staunch investors in its unique technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NanoViricides Inc.
NanoViricides develops nanotechnology-based antiviral drugs. Being an early-stage company, its monthly valuation is based on the potential of its scientific platform. News about preclinical studies and development progress are the main drivers of its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma virus
This chart reflects the dynamics of the biotech sector, particularly the antiviral drug segment. For NanoViricides, an early-stage company, this is the backdrop. Its movements demonstrate how investor expectations surrounding its unique nanotechnology platform influence its valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
NanoViricides is developing drugs to treat viral infections based on its nanomedicine platform. This is a high-risk area. The overall market chart provides only background information, while NanoViricides' performance is driven by news of clinical trials, which can trigger sharp movements counter to any market trend, as is typical in biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NanoViricides Inc.
NanoViricides, which develops nanotechnology-based antiviral drugs, is extremely sensitive to epidemiological news. Its weekly stock price is a strong reaction to preclinical trial data and any news about viral outbreaks, such as influenza, herpes, or coronaviruses.
Weekly dynamics of market capitalization of the market segment - Pharma virus
NanoViricides operates in the biotech sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment. The chart will show whether NNVC is perceived by the market as a promising player or simply part of the overall flow of antiviral developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, NanoViricides often defies general market trends. Its fate depends not on GDP or inflation, but on news about viral threats and research results. The chart below clearly demonstrates how NNVC shares can live a life of their own, separate from the broader market.
Market capitalization of the company, segment and market as a whole
NNVC - Market capitalization of the company NanoViricides Inc.
NanoViricides' market capitalization dynamics tell the story of a new approach to fighting viruses. The chart of this company, which develops "nano-traps" for viruses, reflects investor hopes for its platform. Its speculative dynamics reflect the market's assessment of its science and the long journey from the lab to an approved drug.
NNVC - Share of the company's market capitalization NanoViricides Inc. within the market segment - Pharma virus
NanoViricides develops drugs based on its unique nanomedicine technology to combat viral infections. Its market share is based on this innovative approach. The chart shows the market value of its platform, which mimics human cells to capture and destroy viruses.
Market capitalization of the market segment - Pharma virus
NanoViricides develops nanotechnology-based antiviral drugs, aiming to create "traps" for viruses. The chart below shows the pharmaceutical sector's market capitalization. This represents one of the most innovative approaches to combating viral infections.
Market capitalization of all companies included in a broad market index - GURU.Markets
NanoViricides develops nanotechnology-based drugs for the treatment of viral diseases. Its market capitalization is a bet on its unique antiviral platform. The chart below shows the economic weight of companies at the intersection of nanotechnology and medicine.
Book value capitalization of the company, segment and market as a whole
NNVC - Book value capitalization of the company NanoViricides Inc.
NanoViricides is based on a unique nanomedicine platform. The company's book value reflects its patents for "nanoviricides," which are designed to capture and destroy viruses, as well as its pilot production site and R&D capital. The chart below shows how the company is building the financial foundation for its breakthrough antiviral technology.
NNVC - Share of the company's book capitalization NanoViricides Inc. within the market segment - Pharma virus
NanoViricides, Inc. develops antiviral drugs using its R&D laboratories and pilot production facilities. The S_BCap_Seg chart shows its share of the physical infrastructure of the innovative pharmaceutical sector.
Market segment balance sheet capitalization - Pharma virus
NanoViricides develops antiviral drugs based on nanotechnology. Its assets include a unique scientific platform and patents. The chart shows that its balance sheet is virtually devoid of tangible assets, which is typical for a biotech company focused on research and development.
Book value of all companies included in the broad market index - GURU.Markets
NanoViricides' assets represent a unique platform for combating viruses. The company's book value reflects its R&D laboratories and pilot production facility, where nanomachines capable of attacking and destroying viral particles are being created. This represents capital invested in a fundamentally new approach to the development of antiviral drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NanoViricides Inc.
NanoViricides develops nanotechnology-based drugs to combat viral infections. The company's book value is low. Its market capitalization is a pure valuation of its unique platform technology and its potential to create effective antiviral agents.
Market to book capitalization ratio in a market segment - Pharma virus
NanoViricides develops antiviral drugs based on nanotechnology. Its value lies in its unique scientific platform. The chart shows how market expectations for its virus-capturing technology compare to its tangible assets. It's betting on a breakthrough in the treatment of viral infections.
Market to book capitalization ratio for the market as a whole
NanoViricides develops nanotechnology-based drugs to combat viral infections. The company's value lies in its unique platform technology. The market evaluates the future potential of the technology, not the labs. The chart illustrates how investor expectations are driving market capitalization away from its modest book value.
Debts of the company, segment and market as a whole
NNVC - Company debts NanoViricides Inc.
NanoViricides, a company developing antiviral drugs, is using debt to finance its unique nanotechnology platform. This chart shows the capital raised to conduct lengthy and expensive preclinical and clinical trials. This is a bet on a new approach to combating viral infections.
Market segment debts - Pharma virus
NanoViricides develops nanotechnology-based drugs to combat viral infections. Like other biotech companies in the R&D stage, it has no sales revenue. This graph reflects its reliance on equity capital to fund its unique and expensive research aimed at creating a new class of drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NanoViricides Inc.
NanoViricides develops nanotechnology-based antiviral drugs. This chart reflects its financial structure. For a company developing revolutionary drugs, raising debt is a very risky move. It demonstrates how high the stakes are in the race to create an effective treatment against viral threats.
Market segment debt to market segment book capitalization - Pharma virus
NanoViricides develops nanotechnology-based antiviral drugs. This biotech industry chart illustrates how the sector as a whole funds breakthrough but high-risk research. It provides context for assessing the company's financial strategy in one of the most advanced areas of pharmaceuticals.
Debt to book value of all companies in the market
NanoViricides develops nanotechnology-based antiviral drugs targeting a broad range of viruses. The biotech sector requires massive investment. The chart showing the overall debt-to-book value ratio of the market demonstrates how willing investors are to finance breakthrough but risky technologies, which determines NanoViricides' future.
P/E of the company, segment and market as a whole
P/E - NanoViricides Inc.
NanoViricides develops drugs to treat viral infections using its unique nanotechnology platform. This chart reflects the company's belief in its innovative approach to fighting viruses. Its value reflects the willingness of investors to fund research that could lead to the development of universal antiviral agents effective against a wide range of diseases.
P/E of the market segment - Pharma virus
NanoViricides, like other biotechs, belongs to a sector with high expectations. This chart shows the average P/E for this industry. Comparing the company's P/E to this benchmark allows us to understand how disruptive investors consider its nanotechnology platform for fighting viruses compared to other antiviral technologies.
P/E of the market as a whole
NanoViricides develops nanomedicines for the treatment of viral infections. Its unique technology enables the creation of virus traps that are expected to be effective even against mutating strains. This chart illustrates the risk appetite in biotech. The company's valuation is based on investors' belief in the breakthrough potential of its platform and is highly sensitive to news about preclinical and clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NanoViricides Inc.
NanoViricides develops nanotechnology-based drugs for the treatment of viral infections. The chart shows investor expectations, which are entirely dependent on the success of its unique platform in clinical trials. This is a long-term bet on the company's ability to create effective, broad-spectrum antiviral agents.
%20P%2FE%20NanoViricides%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NanoViricides-Inc.&v=1772513610097 "Chart of the company's future (projected) P/E NanoViricides Inc.")
Future (projected) P/E of the market segment - Pharma virus
NanoViricides develops nanomedicines to treat viral infections by creating viral decoys that mimic human cells. This chart shows its future profitability expectations, allowing one to assess how highly the market values its unique platform for combating a wide range of viruses.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772513610117 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
NanoViricides, Inc. develops nanotechnology-based drugs for the treatment of viral diseases. It is a high-risk biotech company, whose value is based on the potential of its unique platform. The company's valuation is not based on current market earnings expectations, but rather on a scientific breakthrough.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513610178 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NanoViricides Inc.
NanoViricides, Inc. develops treatments for viral infections based on its unique nanomedicine technology. While in the preclinical stage, the company incurs significant research expenditures. This chart reflects investments in developing a platform to combat a wide range of viruses, from influenza to herpes, which could generate revenue in the future.
Profit of companies in the market segment - Pharma virus
NanoViricides, Inc. develops nanotechnology-based drugs for the treatment of viral infections. This chart shows the overall profitability of the antiviral segment. The company's unique platform allows for the creation of virus "traps." While it is in the research stage, it is not profitable, but its technology could be a breakthrough in the fight against a wide range of viral diseases.
Overall market profit
NanoViricides, Inc. develops treatments for viral infections using its unique nanomedicine technology. The company's potential depends on the success of its developments in combating viruses such as influenza and COVID-19. This graph illustrates general economic cycles, as the need for effective antiviral drugs exists regardless of the economic situation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NanoViricides Inc.
NanoViricides develops antiviral drugs based on its unique nanomedicine technology. This chart reflects analysts' future revenue expectations, based on the long-term potential of the platform to combat a broad range of viruses. It demonstrates the market's confidence in the company's ability to successfully complete preclinical and clinical trials.
%20profit%20of%20the%20company%20NanoViricides%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NanoViricides-Inc.&v=1772513610482 "Graph of future (projected) profit of the company NanoViricides Inc.")
Future (predicted) profit of companies in the market segment - Pharma virus
NanoViricides, Inc. develops nanomedicines for the treatment of viral infections. This chart shows profitability forecasts for the antiviral pharmaceutical segment. It reflects expectations for new antiviral technologies, particularly in light of global pandemic threats, which is fueling interest in the company's developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772513610519 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
NanoViricides develops antiviral drugs. Their success depends on scientific breakthroughs and funding. Expectations for overall market returns, reflected in the chart, influence investors' risk appetite. During periods of economic optimism, investments in biotechnology increase, which is vital for conducting expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513610555 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NanoViricides Inc.
NanoViricides, Inc. develops nanotechnology-based antiviral drugs. The company does not yet have commercial products and, consequently, no revenue. P/S will become a key indicator after the approval of the first drug, reflecting investor confidence in the potential of its unique technological platform.
P/S market segment - Pharma virus
NanoViricides, Inc. develops antiviral drugs based on its unique nanotechnology platform, which mimics human cells to capture and destroy viruses. Their valuation is based on the potential of this platform. The chart shows the market's confidence in their breakthrough scientific approach to treating viral infections such as COVID-19 and influenza.
P/S of the market as a whole
NanoViricides develops nanomedicines for the treatment of viral infections. The company has no revenue, and its valuation depends entirely on the success of its unique technology platform. This chart, showing how the market values real revenue, clearly demonstrates that NanoViricides is a venture bet on a new approach to fighting viruses.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NanoViricides Inc.
NanoViricides develops nanomedicines to treat viral infections. Its unique technology mimics cell receptors to "catch" viruses. This chart shows investor expectations for future revenue from this platform technology, which can be applied to create drugs against a wide range of viruses.
%20P%2FS%20NanoViricides%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NanoViricides-Inc.&v=1772513610680 "The graph of the company's future (projected) P/S NanoViricides Inc.")
Future (projected) P/S of the market segment - Pharma virus
NanoViricides, Inc. develops antiviral drugs based on its unique nanomedicine technology. This chart shows how the market views the future potential of its platform for combating various viral infections. It compares it to other pharmaceutical companies, reflecting investor confidence in its breakthrough approach to drug discovery.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772513610687 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
NanoViricides develops antiviral drugs based on its proprietary nanotechnology platform. The company aims to create treatments for a wide range of viruses, including influenza and COVID-19. This chart shows revenue expectations for the entire market, and NNVC demonstrates how pandemics have increased investor interest in innovative antiviral technologies.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513610732 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NanoViricides Inc.
NanoViricides, Inc. is a biotechnology company developing treatments for viral infections based on its unique nanomedicine technology. Being in the preclinical and clinical stages of research, the company does not yet have any commercial products, so its revenue on this graph is typically zero.
Sales of companies in the market segment - Pharma virus
NanoViricides is developing antiviral drugs based on its unique nanomedicine technology. At this stage of development, its revenue is likely derived from grants or partnerships. This chart allows investors to assess the level of external funding supporting its research.
Overall market sales
NanoViricides, Inc. develops drugs to treat viral infections. As pandemics have shown, the need for antiviral drugs is not dependent on economic cycles and can arise unexpectedly. This graph does not reflect the specific risks and opportunities of the company, whose success depends on scientific breakthroughs and the epidemiological situation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NanoViricides Inc.
NanoViricides develops treatments for viral infections based on its unique nanomedicine technology. Its revenue forecast depends on the success of clinical trials. This chart reflects analysts' speculative expectations regarding the commercial potential of its platform for combating viruses such as influenza and COVID-19.
%20sales%20of%20the%20company%20NanoViricides%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NanoViricides-Inc.&v=1772513610834 "Schedule of future (projected) sales of the company NanoViricides Inc.")
Future (projected) sales of companies in the market segment - Pharma virus
NanoViricides develops nanomedicines for the treatment of viral infections. This chart shows projected revenues for the entire antiviral pharmaceutical segment. It helps assess how large and rapidly growing analysts see this market, especially in light of global epidemiological threats, which is important for assessing the potential of NanoViricides' technology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772513610867 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
NanoViricides develops nanomedicines for the treatment of viral infections. The company's success depends on the results of clinical trials and potential pandemics. The overall economic situation, shown in this chart, influences government funding for infectious disease programs and the investment climate for biotech companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513610887 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NanoViricides Inc.
NanoViricides, Inc. develops treatments for viral infections based on its unique nanomedicine technology. This chart reflects the financial picture at the advanced preclinical and clinical research stages. It shows the level of investment in research, the success of which determines the company's future.
Market segment marginality - Pharma virus
NanoViricides, Inc. develops specialized nanomedicines for the treatment of viral infections by creating "traps" for viruses. This graph shows the average profitability in the antiviral pharmaceutical sector. It allows one to estimate the financial advantage the company's unique technological platform can provide compared to traditional approaches in this field.
Market marginality as a whole
NanoViricides, Inc. is developing a platform for creating antiviral drugs. This is a high-tech and risky business. This graph of average market returns illustrates the current situation, while pandemics and the threat of new viruses make technologies like those developed by NanoViricides strategically important for global health.
Employees in the company, segment and market as a whole
Number of employees in the company NanoViricides Inc.
NanoViricides develops antiviral drugs based on its unique nanomedicine platform. Its small scientific team is entirely focused on research and development. This graph illustrates that in early-stage biotech, value is created not by the number of employees, but by the quality of science and intellectual property.
Share of the company's employees NanoViricides Inc. within the market segment - Pharma virus
NanoViricides, Inc. develops nanomedicines for the treatment of viral infections. This chart illustrates its unique technological approach. It reflects the proportion of nanotechnologists, virologists, and chemists working on the creation of "virus traps"—a new class of antiviral agents—that this innovative company brings together under its wing.
Number of employees in the market segment - Pharma virus
NanoViricides, Inc. develops antiviral drugs based on its unique nanomedicine technology. This chart shows employment in the viral pharmaceuticals sector. The growing number of scientists in this field reflects the ongoing threat of viral pandemics and the need to develop innovative platforms for the rapid development of effective drugs.
Number of employees in the market as a whole
NanoViricides, Inc. develops nanotechnology-based antiviral drugs. Combating viral infections remains a major challenge for global healthcare. This chart shows the overall employment landscape, where biotech companies working on breakthrough technologies contribute to the knowledge-intensive sector of the economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NanoViricides Inc. (NNVC)
NanoViricides, Inc. is developing a new platform to combat viruses. This is a highly research-intensive task. This chart shows how the market views the potential of this unique technology. The high market capitalization per employee reflects investors' belief that the team can create a universal "weapon" against multiple viral threats.
%20of%20the%20company%20NanoViricides%20Inc.%20(NNVC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NanoViricides-Inc.-NNVC&v=1772513611117 "Chart of market capitalization per employee (in thousands of dollars) of the company NanoViricides Inc. (NNVC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
NanoViricides develops antiviral drugs based on nanotechnology. For such an innovative company, its market capitalization per employee reflects the uniqueness of its scientific platform. Its significant outperformance of industry benchmarks indicates investors' high hopes for a breakthrough in the treatment of a wide range of viral diseases.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772513611139 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
NanoViricides is developing a new class of nanotechnology-based drugs for the treatment of viral infections. This is at the cutting edge of science. This chart reflects the investors' high expectations, with the high valuation per employee demonstrating their belief that the team of scientists will be able to create a revolutionary antiviral platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513611162 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NanoViricides Inc. (NNVC)
NanoViricides is a preclinical biotech company developing a "nanoviricide" platform to combat viral infections. This involves deep science and R&D. This negative graph shows how much capital the company is investing in each scientist trying to prove the effectiveness of this unique nanotechnology.
%20Chart%20NanoViricides%20Inc.%20(NNVC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NanoViricides-Inc.-NNVC&v=1772513611169 "Company Profit Per Employee (in thousands of dollars) Chart NanoViricides Inc. (NNVC)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
NanoViricides is developing antiviral drugs based on its unique nanomedicine technology. This graph illustrates the potential value of their innovative platform. It shows the enormous profit potential of a successful drug capable of combating a wide range of viruses, demonstrating the effectiveness of their scientific approach compared to traditional methods.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772513611203 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
NanoViricides, Inc. develops antiviral drugs based on its nanomedicine platform. It is a deep R&D business. The revenue per employee (likely negative) demonstrates the "cost" of the research team. It reflects the investment required per scientist to create innovative treatments for viruses like influenza or COVID-19.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513611232 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NanoViricides Inc. (NNVC)
NanoViricides, Inc. develops nanotechnology-based antiviral drugs. This graph is typical for a biotech company in the R&D stage—there is no revenue per employee. It illustrates the company's scientific potential. Approval and commercial launch of one of the drugs could lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NanoViricides-Inc.-NNVC&v=1772513611244 "Sales chart per company employee NanoViricides Inc. (NNVC)")
Sales per employee in the market segment - Pharma virus
NanoViricides (NNVC) is a biopharmaceutical company developing antiviral drugs based on its nanotechnology platform (nanoviricides®). This chart shows the average revenue per employee in the pharmaceutical segment. Being in preclinical and early clinical development, NNVC has no commercial sales. Comparison with the benchmark highlights their focus on R&D.
Sales per employee for the market as a whole
NanoViricides (NNVC) is a preclinical biotech company developing antiviral drugs. It's even earlier in the development cycle than HOTH. It has no revenue, and its revenue metric is zero. It's a pure venture investment in a scientific platform that may (or may not) lead to a cure many years down the road.
Short shares by company, segment and market as a whole
Shares shorted by company NanoViricides Inc. (NNVC)
NanoViricides is a biotech company that has been claiming for decades to be developing a universal platform (nano-drugs) against viruses, including influenza and COVID-19. This chart shows that investors consider it a "perpetual startup." Bears are betting that the company lacks real science and exists solely through shareholder dilution.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NanoViricides-Inc.-NNVC&v=1772513611377 "Short Shares Chart for the Company NanoViricides Inc. (NNVC)")
Shares shorted by market segment - Pharma virus
NanoViricides (NNVC) is a preclinical company that has been promising for years to create "nanoviricides" for treating viruses, from influenza to herpes. This chart illustrates the pessimism in the sector. The surge in shorts across the industry is a bet that this entire scientific platform is "science fiction." Investors don't believe NNVC's technology will ever prove its worth and reach the market.
Shares shorted by the overall market
NanoViricides is developing a platform for creating antiviral drugs. This technology has enormous potential, but it's still in the R&D stage. This chart illustrates the overall market pessimism. When fears mount, investors are reluctant to bet on "forever" R&D. They're selling off NNVC shares, fearing the company will never be able to develop its platform into a commercial product.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NanoViricides Inc. (NNVC)
NanoViricides (NNVC) develops antiviral drugs using its unique nanotechnology platform. The company often attracts attention during virus outbreaks. This indicator measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) on virus news or "oversold" (below 30) during quiet periods.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NanoViricides-Inc.-NNVC&v=1772513611421 "RSI 14 indicator chart for the company's stock NanoViricides Inc. (NNVC)")
RSI 14 Market Segment - Pharma virus
NanoViricides (NNVC) is a biotech company developing "nanovirusides." These are drugs that are designed to "catch" and neutralize viruses, like Velcro. This chart tracks overall sentiment in the Pharma/Virology sector. It helps investors understand whether the entire sector is overheated (as during the pandemic) or oversold.
RSI 14 for the overall market
NanoViricides (NNVC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NNVC (NanoViricides Inc.)
NanoViricides is a biotech company developing a platform of "nanoviricides"—drugs designed to "catch" and kill viruses, including influenza and COVID-19. This chart shows the speculative average 12-month price target from analysts, which is entirely dependent on their faith in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NNVC-NanoViricides-Inc.&v=1772513611470 "A chart showing analyst consensus forecasts for the expected stock price. NNVC (NanoViricides Inc.)")
The difference between the consensus estimate and the actual stock price NNVC (NanoViricides Inc.)
NanoViricides is a biotech company developing a unique platform of "nanoviricides"—nano-traps for viruses (influenza, COVID). This chart shows how far the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this futuristic, yet risky, R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NNVC-NanoViricides-Inc.&v=1772513611490 "A chart showing the difference between the consensus forecast and the actual stock price. NNVC (NanoViricides Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
NanoViricides (NNVC) is a biotech company developing "nanoviricides"—nano-traps designed to "catch" and neutralize viruses (flu, COVID). This chart shows the overall expectations of analysts for the pharmaceutical sector. It reflects the confidence of experts in this innovative antiviral platform.
Analysts' consensus forecast for the overall market share price
NanoViricides is a biotech company developing a platform of "nano-viricides"—drugs designed to "catch" and destroy viruses (influenza, COVID, herpes). This chart shows the overall "risk appetite" in the market. For NanoViricides, a company with a breakthrough but risky technology, overall market optimism is critical to attracting capital for long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NanoViricides Inc.
NanoViricides is an R&D company that has been working on nanovirology for decades. Their specialty is nano-traps designed to deceive and capture viruses (flu, herpes, COVID). This chart is a summary indicator of faith and disappointment. It reflects their (very slow) R&D progress and the market's speculative faith in their futuristic (but unproven) technology.
AKIMA Market Segment Index - Pharma virus
NanoViricides (NNVC) is a biopharmaceutical company developing nanoviricides—drugs designed to trap and destroy viral particles like a trap. They target influenza, herpes, and COVID-19. The chart shows the segment average, helping investors assess how this unique antiviral platform compares to the industry average.
The AKIM Index for the overall market
NanoViricides is a company developing nanomedicines to combat viral infections (influenza, COVID, shingles). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this long-term R&D history compares to overall economic trends in the healthcare sector.
